Central nervous system (CNS) PTLD generally carries a dismal prognosis. It is seen in both children and adults and about half of cases occur in isolation, with the rest occurring in the setting of ...

Recipients of solid-organ transplants receive immunosuppressive therapy to prevent allograft rejection. Immunosuppressive therapy can be divided into induction therapy, administered in the ...

Does Epstein-Barr virus (EBV) prophylaxis lower the risk of post-transplantation lymphoproliferative disorder (PTLD)? Investigations conducted to date, often involving small populations or historical ...

July 11, 2008 (Paris, France) — The retrospective evaluation of a preventative and preemptive intervention for pediatric recipients of liver transplants has shown that a combination of prophylactic ...

Fred Hutchinson Cancer Center is home to some of the world’s most advanced cancer treatments, including CAR T-cell therapy for post-transplant lymphoproliferative disorder (PTLD). Physicians in the ...

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. There were seven kidney, three heart, and one liver transplant ...

Please provide your email address to receive an email when new articles are posted on . More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant ...

According to the CRL, the product could not be approved based on inspection findings at a third party manufacturing facility. The Food and Drug Administration (FDA) has issued a Complete Response ...

Transplants can trigger EBV reactivation, leading to EBV-positive PTLD, with poor survival if rituximab fails. Tabelecleucel (tab-cel) shows promise in treating refractory EBV+ PTLD, with significant ...

First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ ...